58
Pharma & HealthcareHold
DSP Healthcare
DSP · Direct–Growth · rank #6 of 19 by Smart Score
Data updated
Trailing returns
1 Year
16.5%
+18.6% vs index
3 Years
21.8%
+12.0% vs index
5 Years
15.5%
+6.0% vs index
Since launch
23.3%
Year-by-year performance
2021
+25.1%-5.5% vs index
2022
-6.5%-10.3% vs index
2023
+36.8%+10.3% vs index
2024
+42.6%+27.0% vs index
2025
-4.5%-12.2% vs index
2026
+17.9%+21.5% vs index
Why this score
DSP Healthcare scores 58/100 — #6 of 19 Pharma & Healthcare fund (Hold). It stands out for expense ratio and fund size — beating 92% of peers on expense ratio. The main drag is its 1y return (better than only 38% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
Expense ratio0.73% · 92nd percentile in category
Fund size3835.28 Cr · 82nd percentile in category
Sharpe ratio1.11 · 66th percentile in category
Sortino ratio1.68 · 63rd percentile in category
Alpha4.31 · 41st percentile in category
1Y return16.48% · 38th percentile in category
Top holdings
1.Ipca Laboratories Ltd8.74%
2.Sun Pharmaceutical Industries Ltd7.95%
3.Sai Life Sciences Ltd.7.45%
4.Cipla Ltd7.35%
5.Apollo Hospitals Enterprise Ltd6.47%
30 disclosed equity positions · portfolio as of Aug 2026 · weights are % of total corpus.